CRCP (Cripto-1) is a glycosylphosphatidylinositol (GPI)-anchored protein belonging to the epidermal growth factor (EGF)-CFC protein family. Initially identified for its role in embryonic development, CRCP acts as a co-receptor for nodal signaling, a pathway critical for cell differentiation and tissue patterning. It interacts with TGF-β family ligands, facilitating activation of downstream Smad2/3 pathways. Beyond embryogenesis, CRCP is implicated in cancer progression, where its aberrant expression is observed in various malignancies, including breast, colon, and lung cancers. Overexpression of CRCP correlates with enhanced tumor cell proliferation, epithelial-mesenchymal transition (EMT), metastasis, and resistance to apoptosis, making it a potential therapeutic target.
CRCP antibodies are essential tools in both research and diagnostics. They enable detection of CRCP expression in tissues or cell lines via techniques like immunohistochemistry, Western blotting, and flow cytometry. In translational research, these antibodies help elucidate CRCP’s oncogenic mechanisms, including its interplay with signaling pathways like Wnt/β-catenin and PI3K/AKT. Clinically, CRCP antibodies are explored for prognostic applications, as elevated CRCP levels often predict poorer patient outcomes. Additionally, therapeutic monoclonal antibodies targeting CRCP are under investigation to block its oncogenic functions. Despite progress, challenges remain in understanding tissue-specific roles and optimizing antibody specificity. Overall, CRCP antibodies bridge fundamental research and clinical innovation in oncology.